

Industry Partnerships

COMPANY	PROJECT TITLE
ARTIFICIAL PANCREAS	
Animas Corporation + Dexcom	Development of a semi-closed-loop insulin delivery system utilizing the Animas insulin pump and Dexcom continuous glucose sensor
Arecor	Stable ultra-concentrated insulin compositions
BD Diabetes Care	Insulin infusion partnership Glucose binding protein based continuous glucose monitor (NCT01469715) Artificial pancreas system with advanced integrated CGM sensor and infusion set
Dexcom	Development of a relay receiver for continuous glucose monitor (CGM) wireless connectivity to an artificial pancreas controller
Dose Safety Company	Evaluation of FL controller during exercise and high CHO/high fat meals
GluSense	Prototype development and pre-clinical evaluation of an innovative cell based, implantable continuous glucose monitor (CGM)
Latitude Pharmaceuticals	Stabilized glucagon nanoemulsions
Tandem	Dual drug infusion pump for insulin and pramlintide (Symlin®)
Thermalin	Ultra-rapid insulin analogs with shortened duration of signaling
BETA CELL REPLACEMENT	
Athersys	Genome-wide discovery of pancreatic islet cell differentiation factors using MAPC adult stem cells
CyThera (ViaCyte now)	Derivation, characterization and distribution of embryonic stem cell lines
ES Cell International	Isolation of clinically-compliant human embryonic stem cells
Living Cell Technologies	An open-label investigation in New Zealand of the safety and effectiveness of DIABECCELL® in patients with T1D (NCT00940173)
Noveome Biotherapeutics	Differentiation of amnion-derived cells to clinically viable islets for transplantation
Novocell (ViaCyte now)	Encapsulated human islet allografts for the treatment of diabetes
Plureon Corporation	Generation of pancreatic beta cells from pluripotent adult stem cells in human adipose tissue
Sanofi + Genzyme	Development partnership for T1D therapeutics development
ViaCyte	Cell therapy for diabetes Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk T1D
Ximerex	Islet transplantation into animal models using chimeric donor animals
BETA CELL REGENERATION	
Biogen	Treatment with an Fn14 agonist as a potential approach to achieve islet cell reconstitution in T1D TWEAK as a potential pancreatic regeneration factor
California Institute for Biomedical Research	Calibr-JDRF translational academic research partnership
Develogen AG	Discovery and development of beta cell regeneration drugs for T1D
GNF Novartis	Discovering new biology and translating this knowledge into innovative treatments for T1D
Housey Pharmaceutical Research Laboratories	Discovery and development of antidiabetic drugs
NGM Biopharmaceuticals	Discovery of novel gastrointestinal factors that enhance beta cell growth Beta cell regeneration biologics discovery
Transition Therapeutics	Stimulation of islet cell regeneration in T1D with GLP-1 and gastrin
IMMUNOTHERAPIES	
Avidex	Monoclonal T cell receptor therapeutics in the treatment of T1D
Axxam	Identification of Kv1.3 blockers for the treatment of T1D Discovery research of innovative immunosuppressant for prevention of T1D
Bayhill Therapeutics	Phase I clinical trial of BHT-3021, an antigen-specific immunotherapeutic DNA vaccine for T1D (NCT00453375)
EpiVax	T1D tolerance induction with natural regulatory T cell epitopes
GNF Novartis	Novel strategies for inducing antigen-specific immune tolerance in T1D
Immunocore	A novel monoclonal T cell receptor therapeutic targeted towards a proprietary antigen associated with T1D
MacroGenics	A phase II/III, randomized, double-blind study to evaluate efficacy and safety of teplizumab (MGA031), an anti-CD3 monoclonal antibody, in children and adults with recent-onset T1D (NCT00385697)
REGiMMUNE	Antigen-specific therapeutic RGI-3100 for T1D
Selecta Biosciences	Diabetes antigen specific tolerance induction by targeted nanoparticles
Tolerx	Human clinical trials of TRX4 (otelixizumab), an anti-CD3 monoclonal antibody, in patients with T1D (NCT00451321 , NCT00678886)
GLUCOSE CONTROL	
Amylin Pharmaceuticals	Combined metreleptin and insulin therapy for T1D (NCT01268644)
Lexicon Pharmaceuticals	LX4211 (sotagliflozin) in T1D with high unmet need (NCT02383940)
SmartCells	Proof-of-concept for an injectable, glucose-regulated insulin for T1D (NCT02269735)
PREVENTION	
CoMentis	Proof-of-concept testing of GTS-21, a selective ±7-nAChR agonist, to prevent or delay the onset of T1D
DiabetOmics	Point-of-care assays for detection of islet autoantibodies (Insudex)
Osiris Therapeutics	Prochymal for the treatment of patients with new onset T1D
COMPLICATIONS	
AGTC	Study of anti-neovascular genes for treatment of diabetic retinopathy
CoMentis	Proof-of-concept testing of mecamlamine (ATG-003) as topical anti-angiogenic therapy in patients with diabetic macular edema (NCT00536692)
Genentech	Ranibizumab (Lucentis®) for edema of the macula in diabetes: A phase II study—the READ 2 study (NCT00407381) Combined approach to treatment using ranibizumab (Lucentis®) and efalizumab for diabetic macular edema study: The CAPTURE study (NCT00676559) Ranibizumab (Lucentis®) for edema of the macula in diabetes: Protocol 3 with high dose—the READ 3 study (NCT01077401)
iCo Therapeutics	iCo-007 as monotherapy or in combination with ranibizumab (Lucentis®) in the treatment of diabetic macular edema (the iDEAL study) (NCT01565148)
KalVista Pharmaceuticals	The development of intravitreal plasma kallikrein inhibitors (KDVO01) for diabetic macular edema (DME) (NCT02193113)
Sangamo BioSciences	A phase II clinical trial of SB-509, a novel VEGF-activator, in patients with diabetic neuropathy (NCT00406458 , NCT01079325)